Fresh2 Group Limited (FRES)
Company Description
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China.
It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc.
In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution.
Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners.
The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023.
The company was incorporated in 2010 and is based in New York, New York.
| Country | United States |
| IPO Date | Jan 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Haohan Xu |
Contact Details
Address: 650 5th Ave New York City, New York United States | |
| Website | https://fresh2.co |
Stock Details
| Ticker Symbol | FRES |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US03635R3057 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Sunil Pandit | U.S. Chief Executive Officer |
| Haohan Xu | Chairman of the Board & Chief Executive Officer |
| Xiaoyu Li | Director & Chief Financial Officer |
| Weidong Dai | China President |
| Yidong Hu | Chief Strategy Officer |